[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gingivitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gingivitis":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,53,0,25,[9,51,75,99,125,160,182,218,239,261,281,307,326,351,374,393,418,438,460,481,506,531,548,568,598],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100516585","intraoral-scanners-as-periodontal-and-dental-pathologies-diagnosis-tools-100516585",false,"NCT06006429","Intraoral Scanners as Periodontal and Dental Pathologies Diagnosis Tools","Digital Extraction and Scientific Visualization of Clinical Characteristics From 3D Data From Intraoral Scanners for Dental and Periodontal Pathologies Research : Computer Formalization and Feasibility Study","Odonto3D","Inclusion Criteria:\n\n* adultes\n* consulting the Dental Care Service of the university hospital of Reims\n* presenting at least one gingival recession\n* presenting at least 10 pairs of opposing teeth\n* speaking French\n* who signed the informed consent form\n* affiliated to the French Social Security system\n\nExclusion Criteria:\n\nPatients presenting :\n\n* pregnancy or breastfeeding\n* orthodontic treatments\n* patients under legal protection, trusteeship or guardianship\n* unable to understand auto-questionnary",true,"ALL","18 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","Periodontal diseases and dental pathologies are highly prevalent oral diseases. Thirty-three to fifty percent of adult population presented at least one untreated caries and more than 50% of French population are affected by severe periodontitis. These diseases affect dental organ or periodontal attached system but could have negative impact on general health, quality of life, word and individual well-being. Association between chronic diseases as diabetes, rheumatoid arthritis, cardiovascular diseases, and oral health have been well investigated. Dental and periodontal diagnosis is dependent of various clinical parameters time consuming and dependent operator. It represents a public health challenge. Informatic analysis detecting diseases could be a time gain and a more precise diagnosis tool. Today, any software or algorithm allow automatized detection, clinical qualitative or quantitative indices recording while these informations are present in numeric models",[29,30,31,32],"Periodontitis","Gingivitis","Dental Caries","Diagnosis",[34,35,36,37],"Periodontal diseases","Dental caries","intra-oral camera","diagnosis","RECRUITING","2026-06-11",{"date":41,"type":42},"2026-06-12","ACTUAL",{"date":44,"type":42},"2022-05-11",{"date":46,"type":23},"2027-12-11",{"name":48,"class":49},"CHU de Reims","OTHER",1,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":18,"sex":19,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":50},"100642564","evaluation-of-gingival-crevicular-fluid-cytokine-profiles-in-children-and-young-adults-with-gingivitis-100642564","NCT07607639","Evaluation of Gingival Crevicular Fluid Cytokine Profiles in Children and Young Adults With Gingivitis","Comparison of Gingival Crevicular Fluid Biomarkers Between Childhood Gingivitis and Adolescent Gingivitis","Inclusion Criteria:\n\n1. Individuals aged 8-12 years (child group) or 15-24 years (young adult group)\n2. Clinical diagnosis of gingivitis\n3. Presence of fully erupted tooth #31 with closed apex\n4. Systemically healthy individuals\n5. No history of periodontal treatment in the last 3 months\n6. No antibiotic or anti-inflammatory drug use in the last 3 months\n7. Good cooperation and willingness to participate\n8. Written informed consent from participants or legal guardians (for minors)\n\nExclusion Criteria:\n\n1. Age 13-14 years (transitional pubertal period)\n2. Presence of periodontitis or other periodontal diseases\n3. Systemic, genetic, or immunological diseases\n4. Acute oral infections or conditions requiring emergency treatment\n5. Orthodontic appliances in the sampling region\n6. Smokers\n7. Pregnant or lactating individuals\n8. Individuals with cognitive, psychological, or physical disabilities affecting cooperation\n9. Inadequate eruption or incomplete root development of tooth #31\n10. Refusal to participate or withdrawal of consent","8 Years","24 Years",{"count":61,"type":23},80,"1 Day","OBSERVATIONAL","This prospective observational case-control study aims to compare gingival crevicular fluid (GCF) biomarker profiles between children and young adults diagnosed with gingivitis. A total of approximately 80 systemically healthy participants will be recruited and divided into two groups: children aged 8-12 years and young adults aged 15-24 years. Individuals aged 13-14 years will be excluded as they represent a transitional pubertal period characterized by significant hormonal fluctuations that may influence inflammatory responses and confound biomarker levels.\n\nClinical periodontal parameters including gingival index, plaque index, bleeding on probing, and probing depth will be recorded. In addition, GCF samples will be collected from a standardized tooth and analyzed for levels of IL-1β, TNF-α, IL-10, and MMP-8 using enzyme-linked immunosorbent assay (ELISA).\n\nThe primary objective of the study is to evaluate and compare inflammatory and anti-inflammatory cytokine profiles between the two age groups. The findings may contribute to understanding age-related differences in gingival inflammatory responses and the potential role of hormonal transition in periodontal disease expression during childhood and early adulthood.",[30],"2026-06-08",{"date":68,"type":42},"2026-06-10",{"date":70,"type":42},"2026-05-22",{"date":72,"type":23},"2027-11",{"name":74,"class":49},"Nigde Omer Halisdemir University",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":24,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":50},"100643026","theranovis-dental-gel-in-patients-with-gingivitis-100643026","NCT07641192","Theranovis Dental Gel in Patients With Gingivitis","The Effects of Theranovis Dental Gel in Patients With Gingivitis: A Prospective Pilot Study","Inclusion Criteria:\n\n* Male and female participants aged over 18 years\n* At least 12 teeth per jaw (natural teeth, including restorations such as crowns and implants)\n* Smokers (less than 10 cigarettes per day)\n* Gingivitis with intact periodontium (probing depth ≤ 3.0 mm, bleeding on probing \\> 10%)\n* Gingivitis with intact periodontium (probing depth ≤ 4 mm, no bleeding on probing at these sites)\n* Periodontal screening index (PSI) up to grade 2\n\nExclusion Criteria:\n\n* Male and female participants under 18 years of age\n* Fewer than 12 teeth per jaw\n* Individuals not capable of giving informed consent\n* Individuals with hypersensitivity or allergies to any of the study product ingredients\n* Patients with periodontitis\n* Patients with non-plaque-induced gingivitis\n* Periodontal screening index (PSI) grade 3 or higher\n* Current antibiotic prophylaxis",{"count":83,"type":23},20,[26],"The aim of this randomized, blinded, controlled study is to compare the theranovis dental gel with a placebo product in order to determine whether an improvement in oral health can be achieved in patients with gingivitis.",[30,87],"Oral Health Care",[89,90],"theranovis dental gel","gingivitis","NOT_YET_RECRUITING",{"date":39,"type":42},{"date":94,"type":23},"2026-06",{"date":96,"type":23},"2027-04",{"name":98,"class":49},"Medical University of Graz",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":24,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":50},"100643649","the-effect-of-vitamin-d-supplementation-on-the-anti-inflammatory-response-in-periodontal-diseases-100643649","NCT07636733","The Effect of Vitamin D Supplementation on the Anti-inflammatory Response in Periodontal Diseases","The Effect of Vitamin D Levels and Supplementation on Anti-inflammatory Response in Periodontal Disease: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Study groups will be formed according to the 2017 Periodontal Disease Classification. Accordingly:\n* Periodontally healthy; absence of bleeding on probing, erythema, edema, patient symptoms, attachment, and bone loss\n* Gingivitis; patients with an average gingival index ≥0.5 according to Löe and Silness\n* Stage I-II periodontitis; patients with CAL 1-2 or 3-4 mm and a maximum PPD ≤5 mm, showing radiographic horizontal bone loss up to the coronal third of the root (15%-33%), but without tooth loss due to periodontitis\n* Stage III-IV periodontitis; Stage 3 and 4 patients with ≥15 teeth in their mouth, with CAL ≥5 and PPD ≥6 in at least 6 areas, and radiographic bone loss extending to the middle or apical third of the root.\n\nExclusion Criteria:\n\n* Individuals who have undergone periodontal treatment in the last 6 months, have systemic diseases (such as diabetes, parathyroid and thyroid-related endocrine diseases) that may affect periodontal status, patients with chronic liver disease, hypoparathyroidism and renal failure, those who have been using medications that may affect periodontal response (aspirin, non-steroidal anti-inflammatory drugs or steroids) for a long time, those who are using additional vitamin D or calcium supplements in the pre-study phase, those who are pregnant or breastfeeding, and those with hypercalcemia and malabsorption syndrome will not be included in the study.","70 Years",{"count":108,"type":23},120,[26],"A review of the literature revealed that while there are studies investigating the relationship between vitamin D and periodontal disease, there are no studies investigating the anti-inflammatory effect of vitamin D on periodontal disease. Investigators hypothesized that the increased incidence of periodontal disease in individuals with vitamin D deficiency might be due not only to pro-inflammatory effects but also to impaired bone metabolism and a decrease in the anti- inflammatory mechanism. Investigators aimed to determine this by comparing serum and DOS levels of 1,25-dihydroxyvitamin D (1,25(OH)2D), 25-hydroxyvitamin D (25(OH)D3), Receptor activator nuclear kappa B ligand (RANKL), osteoprotegerin (OPG), Tumor Necrosis Factor Related Apoptosis induced Ligand (TRAIL), Developmental endothelial locus (Del)-1, Lipoxin, Resolvin, interleukin (IL)-10, and transforming growth factor-β (TGF-β).\n\nThe study will include 120 individuals who are systemically healthy based on clinical and radiographic examinations and diagnosed with Stage I-II periodontitis, Stage III-IV periodontitis, chronic gingivitis, and periodontally healthy. Periodontal clinical parameters (Probing pocket depth (PPD), Clinical attachment level (CAL), Bleeding on probing (BOP), Plaque index (PI), Gingival index (GI)) will be recorded three times: before treatment, and 6 and 12 weeks after treatment. Gingival crevicular fluid (GCF) and serum samples will be collected from participants at baseline and 12 weeks later for biochemical analysis.",[112,30,113],"Periodontal Diseases","Vitamin D Deficiency",[115,90,116,117],"periodontitis","Vitamin D","anti-inflammatory",{"date":68,"type":42},{"date":120,"type":42},"2026-06-03",{"date":122,"type":23},"2026-10-16",{"name":124,"class":49},"Recep Tayyip Erdogan University Training and Research Hospital",{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":133,"minAge":4,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":24,"phases":136,"briefSummary":139,"conditions":140,"keywords":144,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":50},"100625608","phase-2-xylitol-and-the-prevention-of-periodontal-disease-and-preterm-birth-trial-100625608","NCT07424846","Xylitol and the Prevention of Periodontal Disease and Preterm Birth Trial","Xylitol and the Prevention of Periodontal Disease and Preterm Birth (XaPPP) Trial","XaPPP","Inclusion Criteria:\n\n* Able to provide informed consent. For those under 18 years of age, an approval will additionally be sought from the parent or guardian\n* Less than 20 weeks' gestation (by best obstetric estimate)\n* At least 20 natural teeth\n* Planning to deliver at one of the health facilities within the XaPPP trial\n* Receiving antenatal obstetric care at one of the 8 health districts\n* Willing to chew two pieces of gum thrice daily for 5 minutes after the morning, day and evening meals throughout pregnancy\n* Willing to attend all study visits\n* Willing to provide biospecimens (oral, vaginal, placental, breast milk)\n* Willing to undergo at least two dental exams including oral microbiota sampling at study enrolment \\\u003C20 weeks of pregnancy, 28-30 weeks of pregnancy, and 6-8 weeks after giving birth\n* Willing to have their child undergo follow up through at least 12 months after birth including neurodevelopmental examination(s)\n* Speaks Chichewa or English\n\nAll patients who meet inclusion criteria will be approached without regard to sex, race, ethnicity, parents' country of origin, or religious preferences.\n\nExclusion Criteria:\n\n* Those who upon screening and enrolment but dislike the taste of the gum and state they will not chew the gum throughout pregnancy\n* Gravidae with known or suspected non-viable pregnancy (including life threatening congenital anomalies such as cardiac, neurological or others)\n* Pregnant individual has a life-threatening diagnosis such as cancer requiring treatment during pregnancy\n* Pregnant women with a known or suspected morbidly adherent placenta (such as placenta accrete, increta and percreta)\n* Known allergy to xylitol","FEMALE",{"count":135,"type":23},6000,[137,138],"PHASE2","PHASE3","The ground-breaking Prevention of Prematurity and Xylitol (PPaX) cluster randomized controlled clinical trial was conducted in Lilongwe, Malawi and enrolled approximately 10,069 pregnant individuals seeking to evaluate the impact of xylitol-containing chewing gum compared to no chewing gum on reducing the occurrence of maternal periodontal disease, preterm birth, and low birthweight offspring. The premise of this study centers upon the numerous publications supporting a strong association between maternal periodontal disease and preterm birth. Given that xylitol-containing chewing gum is considered a prebiotic and known to reduce cariogenic and periodontopathic bacteria, the study evaluated and discovered a statistically significant reduction in maternal periodontal disease, preterm birth, and low birthweight offspring among pregnant individuals who chewed xylitol-containing chewing gum.\n\nWhile PPaX demonstrated the efficacy of xylitol to reduce preterm birth (PTB), the study had important limitations: (a) PPaX was an unblinded cluster-randomized study with only 8 clusters, 4 with xylitol-containing chewing gum and 4 without any gum (not placebo-controlled); (b) PPaX used a suboptimal dose of 2 grams of xylitol daily which may have reduced the effectiveness of the intervention given that recent literature suggests 5-10 grams\u002Fday more effectively improve oral health; and (c) PPaX did not evaluate infant mortality nor early neurodevelopmental outcomes. Notably, reducing fetal exposure to periodontal disease (PD) as well as PTB may improve neurodevelopmental outcomes for offspring as both prematurity and fetal exposure to inflammation are well-documented risk factors for neurodevelopmental delay (NDD) and infant mortality.\n\nThe investigators will conduct a double-blind, placebo-controlled, individually randomized clinical trial with 3 arms among Malawian pregnant individuals (n=6000) at \\\u003C20 weeks of pregnancy with the co-primary outcomes being the incidence of PTB and low birthweight offspring. The 3 study arms (n=2000 each) will be (a) an optimized dose of xylitol-containing chewing gum (6.4 grams\u002Fday), (b) the PPaX trial xylitol dose (2.1 grams\u002Fday), or (c) flavored sorbitol gum base (placebo control). This trial overcomes the PPaX trial's limitations and will definitively answer whether xylitol prevents PTB in Malawi. The investigators will additionally collect biospecimens from a random sampling of the participants for biobanking for later analysis of inflammatory and microbiome alterations that may occur with xylitol exposure compared with placebo. The investigators hypothesize that pregnant individuals who chew xylitol-containing chewing gum will have a significant reduction in periodontal disease metrics at 28-30 weeks' gestation (e.g. bleeding on probing) as well as offspring with improved neurodevelopmental outcomes as assessed by the Bayley Scales of Infant and Toddler Development 4th edition and reduced risk of adverse pregnancy outcomes including preterm birth.",[141,142,29,30,143],"Preterm Birth","Low Birthweight Neonate","Developmental Delay",[145,146,147,148,115,149,150],"xylitol","preterm birth","prematurity","pregnancy","periodontal disease","chewing gum","2026-06-05",{"date":153,"type":42},"2026-06-09",{"date":155,"type":42},"2026-03-26",{"date":157,"type":23},"2030-09-30",{"name":159,"class":49},"University of Washington",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":168,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":50},"100640564","phase-4-clinical-study-to-collect-and-analyze-dental-plaque-and-oral-health-measures-in-a-population-with-high-plaquelow-gingivitis-and-high-plaquehigh-gingivitis-100640564","NCT07614490","Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque\u002FLow Gingivitis and High Plaque\u002FHigh Gingivitis","Inclusion Criteria:\n\n* Male or female volunteers at least 18 years of age and in general good health.\n* Willing and able to understand and sign the informed consent form.\n* Must have a whole mouth mean TPI score ≥ 3.25\n* N=40 must have moderate-severe gingivitis (Whole Mouth Mean MGI≥2.5 or percent bleeding sites based on EBI ≥20%) and N=40 must have mild gingivitis (Whole Mouth Mean MGI≤2.5 and percent bleeding sites based on EBI\\\u003C20%)\n* Must have at least two areas in the mouth with high plaque\u002Flow inflammation and two areas with high plaque\u002Fhigh inflammation\n* Be willing to conform to the study protocol and procedures.\n* Minimum of 20 natural teeth with scorable facial and lingual surfaces\n\nExclusion Criteria:\n\n* Medical condition which requires premedication prior to dental visits\u002Fprocedure.\n* Known history of allergy to personal care\u002Fconsumer products or their ingredients, relevant to any ingredients in the test products as determined by the study examiner.\n* Active disease of the hard oral tissues.\n* Significant oral soft tissue pathology, excluding plaque-induced gingivitis.\n* Subjects with fixed or removable orthodontic appliances or removable partial dentures.\n* Dental prophylaxis within 30 days prior to study start.\n* Use of antibiotics, antimicrobial drugs, anti-inflammatory drugs, or anticoagulant therapies within 30 days prior to study start.\n* Use of chemotherapeutic oral care products within two weeks prior to study start.\n* Participation in any other clinical study within 30 days prior to enrollment into this study.\n* Subjects who must receive dental treatment during the study dates.\n* Immunocompromised individuals (HIV, AIDS, immunosuppressive drug therapy).\n* Use of smokeless tobacco, vaping, or e-cigarettes or suspected substance abuse.\n* Current smokers (if former smoker, should have stopped at least 1 month prior to Visit 1)\n* Pregnant or lactating subjects, or subjects planning to become pregnant during the course of the study.\n* Medical condition which prohibits not eating\u002Fdrinking or chewing gum for four (4) hours prior to your scheduled visits;\n* Subjects who have an infectious disease and\u002For other blood borne diseases (Hepatitis series, HIV, tuberculosis).",{"count":167,"type":23},100,[169],"PHASE4","The objective of this clinical research study is to collect and analyze plaque and oral health measures in a population with high plaque\u002Flow gingivitis and high plaque\u002Fhigh gingivitis",[30,172],"Plaque",{"date":174,"type":42},"2026-05-29",{"date":176,"type":42},"2026-04-20",{"date":178,"type":23},"2026-10-15",{"name":180,"class":181},"Colgate Palmolive","INDUSTRY",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":18,"sex":19,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":194,"conditions":195,"keywords":199,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":50},"100640692","circadian-clock-proteins-in-gingival-crevicular-fluid-of-individuals-with-and-without-circadian-rhythm-disruption-100640692","NCT07592052","Circadian Clock Proteins in Gingival Crevicular Fluid of Individuals With and Without Circadian Rhythm Disruption","Investigation of Circadian Clock Gene\u002FProteins in Individuals With and Without Disrupted Circadian Rhythm: A Prospective Cross-Sectional Clinical Study","Nursma-CIRC-HG","Inclusion Criteria:\n\n* Aged between 20 and 50 years\n* Systemically healthy\n* Diagnosed as periodontally healthy or with gingivitis based on clinical periodontal examination\n* Having at least 20 natural teeth in the oral cavity\n* Willing to provide written informed consent\n* Agreeing to participate in circadian rhythm assessment and completing the Morningness-Eveningness Questionnaire (MEQ) and Munich Chronotype Questionnaire (MCTQ)\n* Sleep duration of 6-9 hours per day\n* For periodontally healthy: PD \\\u003C=3 mm, BOP \\\u003C10%, CAL=0, no radiographic bone loss\n* For gingivitis: PD \\\u003C=3 mm, 10%\\\u003C=BOP\\\u003C=30%, CAL=0, no radiographic bone loss\n* For circadian rhythm disruption group: being a night-shift worker\n\nExclusion Criteria:\n\n* Use of antioxidant or melatonin supplements\n* Presence of any systemic disease\n* Use of antibiotics, anti-inflammatory drugs, or immunosuppressants within the past 3 months\n* Having received periodontal treatment within the past 6 months\n* Pregnancy or lactation\n* Use of tobacco or tobacco products\n* Presence of acute oral infection, abscess, or advanced periodontal disease\n* Currently undergoing orthodontic treatment or having fixed orthodontic appliances\n* Inability to comply with study procedures or refusal to provide informed consent\n* Self-reported sleep duration less than 6 hours or greater than 9 hours per day","20 Years","50 Years",{"count":193,"type":23},116,"This prospective cross-sectional clinical study aims to investigate the relationship between circadian rhythm disruption and periodontal inflammation by evaluating circadian clock protein levels, inflammatory (IL-1beta) and anti-inflammatory (IL-10) cytokine levels in gingival crevicular fluid (GCF) of individuals with and without circadian rhythm disruption.\n\nParticipants aged 20-50 years will be classified into four groups based on their circadian rhythm status (disrupted\u002Fnormal) and gingival health status (gingivitis\u002Fhealthy). Clinical periodontal parameters including plaque index, gingival index, bleeding on probing, and probing depth will be assessed. Circadian rhythm status will be determined using validated questionnaires (Morningness-Eveningness Questionnaire and Munich Chronotype Questionnaire). Night-shift workers will represent the circadian rhythm disruption group.\n\nGCF samples will be analyzed for circadian clock proteins (BMAL-1, CLOCK, PER-1, PER-2, PER-3, CRY-1, CRY-2, REV-ERB-beta, MTNR1B) and cytokines (IL-1beta, IL-10) using ELISA. Serum cortisol and melatonin levels will be measured for biochemical verification of circadian rhythm status.\n\nGingivitis groups will receive standard periodontal treatment and be re-evaluated at 2 weeks post-treatment. A total of 116 participants (29 per group) are planned for enrollment.",[30,196,197,198],"Circadian Rhythm Disruption","Periodontal Inflammation","Circadian Rhythm Sleep Disorder, Shift Work Type",[200,201,30,202,203,204,205,206,207,208],"Circadian rhythm","Periodontal health","Gingival crevicular fluid","Clock genes","BMAL1","Night shift work","IL-1beta","IL-10","Chronotype","2026-05-11",{"date":211,"type":42},"2026-05-18",{"date":213,"type":23},"2026-08-01",{"date":215,"type":23},"2027-03-01",{"name":217,"class":49},"Inonu University",{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":24,"phases":228,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":50},"100630982","evaluation-of-the-effect-of-the-toothpaste-on-delicate-gums-100630982","NCT07494747","Evaluation of the Effect of the Toothpaste on Delicate Gums","Benchmark Controlled Evaluation of the Effect of a Cosmetic Product in Improving Gums Condition - in Use Test Under Dentist Control","Inclusion Criteria:\n\n1. Healthy male and female subjects (with no specific repartition)\n2. Subjects of Caucasian ethnicity\n3. Subjects aged between 18 and 65 years (extremes included)\n4. Subjects clinically showing moderate gums inflammation (gingivitis grade II, in particular all gingival scores for the mean should be between 1.75 and 2.3, according to Löe and Silness gingival scoring system), in particular:\n\n   1. 40% of the subjects with localized gingivitis (10-30% of evaluated sites with bleeding)\n   2. 60% of them with generalized gingivitis (\\>30% of evaluated sites with bleeding) Repartition to be respected in both study groups.\n5. Subjects with dental plaque (total plaque score at inclusion ≥2)\n6. Subjects registered with the national health service\n7. Subjects certifying the truthfulness of the personal data disclosed to the Principal Investigator or designated personnel\n8. Subjects able to understand the language used in the investigation centre and the information given by the Principal Investigator or designated personnel\n9. Subjects able to respect the instructions given by the Principal Investigator or designated personnel as well as able to respect the study constraints and specific requirements\n10. Subjects who commit not to change their daily routine or lifestyle during the study\n11. Subjects on stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least one month without any changes expected or planned during the study\n12. Subjects informed about the test procedures who have signed a consent form and privacy agreement\n\nExclusion Criteria:\n\n1. Subjects who do not meet the inclusion criteria\n2. Smokers subjects\n3. Subjects planning toothcare during the study period\n4. Subjects using dental apparatus or using dental prosthesis, with generalized tooth recession, with presence of caries, with dental abscess or signs of periodontitis (periodontal probing depth \\>3mm) or active periodontitis\n5. Subjects using other dental hygiene products than provided (e.g. dental floss, interdental brushes, mouthwash, etc) during the study period\n6. Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the Principal Investigator considers dangerous to the subject or incompatible with the requirements of the study\n7. Subjects participating or planning to participate in other clinical trials\n8. Subjects who participated in a similar study without respecting an adequate washout period (at least one month)\n9. Subjects that have food intolerances or food allergies to ingredients of the study product\n10. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the Principal Investigator\n11. Subjects who are currently using food supplement(s) and\u002For products with the same activity as the study product, or who haven't observed an adequate washout period (at least one month)\n12. Subjects admitted to a health or social facility\n13. Subjects planning a hospitalization during the study\n14. Subjects not able to be contacted in case of emergency\n15. Subjects deprived of freedom by administrative or legal decision or under guardianship\n16. Subjects who have or have had a history of alcohol or drug addiction\n17. Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)\n18. Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential).","65 Years",{"count":227,"type":23},60,[26],"The goal of this study is to learn if a toothpaste works to alleviate gingivitis in adults. It will also learn about the safety of the product. The main question it aims to answer is:\n\n• Does the toothpaste help to improve signs of gingivitis? Researchers will compare gingivitis toothpaste to a regular toothpaste to see if it works to improve gingivitis.\n\nParticipants will:\n\n* Use assigned toothpaste daily for 4 weeks\n* Visit the clinic on the established days during 4 weeks for check-ups and evaluation",[30],{"date":232,"type":42},"2026-05-14",{"date":234,"type":42},"2026-03-24",{"date":236,"type":23},"2026-09",{"name":238,"class":181},"Lacer S.A.",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":259,"locationsCount":50},"100624493","development-of-a-self-assessment-tool-for-personalized-preventive-periodontal-care-among-the-saudi-population-using-semi-supervised-learning-100624493","NCT07410351","Development of A Self-Assessment Tool for Personalized Preventive Periodontal Care Among the Saudi Population Using Semi-Supervised Learning","Development and Validation of a Self-assessment Tool for Periodontal Disease Risk Assess Among the Saudi Population Using Semi-supervised Learning","Inclusion Criteria:\n\n* Adult aged 18 years or older\n* Able to read and understand the study information and provide informed consent\n* Able to complete the online questionnaire independently (on a smartphone\u002Ftablet\u002Fcomputer)\n* Willing to undergo a same-visit clinical periodontal examination\n* Has natural teeth present (dentate)\n\nExclusion Criteria:\n\n* Completely edentulous (no natural teeth)\n* Currently undergoing active periodontal treatment (e.g., scaling and root planing) or received periodontal therapy within the past \\[6 months\\]\n* Took systemic antibiotics within the past \\[3 months\\]\n* Unable to complete the questionnaire or examination due to cognitive impairment, severe illness, or communication barriers that prevent informed consent\n* Refuses or is unable to tolerate the periodontal clinical examination",{"count":247,"type":23},393,"This observational study will collect labeled data to assess the accuracy of an online periodontal self-assessment tool in adults. Participants will complete the questionnaire and then undergo a clinical periodontal examination during the same visit. The study will compare questionnaire-based results with clinical examination results to evaluate diagnostic accuracy and agreement.",[112,29,30],[34,251,252],"risk assessment","self-report","2026-04-28",{"date":255,"type":42},"2026-05-05",{"date":257,"type":42},"2026-02-15",{"date":178,"type":23},{"name":260,"class":49},"Universiti Sains Malaysia",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":50},"100633768","oral-hygiene-periodontal-status-and-quality-of-life-100633768","NCT07530978","ORAL HYGIENE, PERIODONTAL STATUS AND QUALITY OF LIFE","EVALUATION OF THE EFFECT OF INDIVIDUALS' ORAL HYGIENE HABITS AND PERIODONTAL STATUS ON QUALITY OF LIFE","Inclusion Criteria:\n\n* Individuals aged 18 years and older\n* Patients presenting to the Department of Periodontology Individuals willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Use of antibiotics or anti-inflammatory drugs within the last 3 months\n* History of periodontal treatment within the last 6 months\n* Pregnancy or lactation\n* Individuals unable to complete the questionnaire",{"count":269,"type":23},160,"This cross-sectional study aims to evaluate the relationship between oral hygiene habits, periodontal status, and oral health-related quality of life in adult individuals. A total of approximately 160 participants attending the Department of Periodontology will be included. Periodontal status will be assessed using standard clinical parameters, including probing depth, clinical attachment loss, bleeding on probing, and plaque index. In addition, the Periodontal Inflamed Surface Area (PISA) will be calculated to quantify inflammatory burden. Oral health-related quality of life will be evaluated using the OSHIP-Perio questionnaire, a validated patient-reported outcome measure specific to periodontal conditions. The study will investigate the association between clinical periodontal findings, oral hygiene practices, and quality of life outcomes. The findings are expected to provide a comprehensive understanding of both clinical and patient-centered aspects of periodontal disease and contribute to improved individualized treatment approaches.",[112,30,29],"2026-04-25",{"date":274,"type":42},"2026-04-30",{"date":276,"type":42},"2025-10-15",{"date":278,"type":23},"2026-06-15",{"name":280,"class":49},"Abant Izzet Baysal University",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":288,"targetDuration":62,"studyType":63,"phases":4,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":306},"100624225","diagnostic-accuracy-of-oral-images-opgs-biomarkers-and-questionnaires-vs-clinical-assessment-for-periodontal-disease-postnct07164573-100624225","NCT07406867","Diagnostic Accuracy of Oral Images, OPGs, Biomarkers and Questionnaires vs. Clinical Assessment for Periodontal Disease (PostNCT07164573)","Diagnostic Accuracy of Oral Images, Orthopantomographs (OPGs), Biomarkers and Self-Reported Questionnaires vs. Clinical Assessment for Detecting Periodontal Health and Disease: a Multi-center Diagnostic Study","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* Seeking dental care at one of the participating study centers.\n* Ability to understand and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Edentulous patients (complete tooth loss).\n* Pregnancy or lactation.\n* History of periodontal therapy (other than supragingival prophylaxis\u002Fcleaning) within the past 12 months.\n* Use of antibiotic medication within the 3 months prior to enrollment.",{"count":289,"type":23},2000,"This multi-center, cross-sectional diagnostic trial evaluates the accuracy of multiple non-invasive screening tools-including self-reported questionnaires, intra-oral photographs, orthopantomographs (OPGs), intraoral scans (IOS), and salivary\u002Fmicrobial biomarkers-for detecting periodontal health and diseases (gingivitis and periodontitis Stages I-IV), using full-mouth clinical periodontal examination as the reference standard. A total of 2,000 participants will be recruited across five international centers. Diagnostic performance (sensitivity, specificity, AUROC) of individual and combined methods will be assessed using logistic regression and machine learning algorithms to establish an optimized multi-modal screening algorithm.",[292,30,29],"Periodontal Disease",[32,294,112,295,296,297],"ArtiLcial Intelligence","Radiography","Machine Learning","Photography","2026-04-24",{"date":274,"type":42},{"date":301,"type":42},"2026-03-01",{"date":303,"type":23},"2029-03-01",{"name":305,"class":49},"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University",3,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":225,"enrollmentInfo":314,"targetDuration":4,"studyType":24,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":4},"100635378","evaluation-of-the-effect-of-the-mouthwash-on-delicate-gums-100635378","NCT07551908","Evaluation of the Effect of the Mouthwash on Delicate Gums","Evaluation of the Effect of a Cosmetic Product in Improving Gums Condition in Use Test Under Dentist Control.","Inclusion Criteria:\n\n1. Healthy male and female subjects (with no specific repartition)\n2. Subjects of Caucasian ethnicity\n3. Subjects aged between 18 and 65 years (extremes included)\n4. Subjects clinically showing moderate gums inflammation (gingivitis grade II, in particular all gingival scores for the mean should be between 1.75 and 2.3, according to Löe and Silness gingival scoring system), in particular:\n\n   1. 20% of the subjects with localized gingivitis (10-30% of evaluated sites with bleeding)\n   2. 80% of them with generalized gingivitis (\\>30% of evaluated sites with bleeding)\n5. Subjects with dental plaque (total plaque score at inclusion ≥2)\n6. Subjects registered with the national health service\n7. Subjects certifying the truthfulness of the personal data disclosed to the Principal Investigator or designated personnel\n8. Subjects able to understand the language used in the investigation centre and the information given by the Principal Investigator or designated personnel\n9. Subjects able to respect the instructions given by the Principal Investigator or designated personnel as well as able to respect the study constraints and specific requirements\n10. Subjects who commit not to change their daily routine or lifestyle during the study\n11. Subjects on stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least one month without any changes expected or planned during the study\n12. Subjects informed about the test procedures who have signed a consent form and privacy agreement\n\nExclusion Criteria:\n\n1. Subjects who do not meet the inclusion criteria\n2. Smokers subjects\n3. Subjects planning toothcare during the study period\n4. Subjects using dental apparatus or using dental prosthesis, with generalized tooth recession, with presence of caries, with dental abscess or signs of periodontitis (periodontal probing depth \\>3mm) or active periodontitis\n5. Subjects using other dental hygiene products than provided (e.g. dental floss, interdental brushes, mouthwash, etc) during the study period\n6. Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the Principal Investigator considers dangerous to the subject or incompatible with the requirements of the study\n7. Subjects participating or planning to participate in other clinical trials\n8. Subjects who participated in a similar study without respecting an adequate washout period (at least one month)\n9. Subjects that have intolerances or allergies to ingredients of the study product Page 8 of 28 Clinical Study Protocol: EC\\_0000149\u002F2026 of 13\u002F03\u002F2026\n10. Subjects under pharmacological treatments that are considered incompatible with the study requirement by the Principal Investigator\n11. Subjects who are currently using products with the same activity as the study product, or who haven't observed an adequate washout period (at least one month)\n12. Subjects admitted to a health or social facility\n13. Subjects planning a hospitalization during the study\n14. Subjects not able to be contacted in case of emergency\n15. Subjects deprived of freedom by administrative or legal decision or under guardianship\n16. Subjects who have or have had a history of alcohol or drug addiction\n17. Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)\n18. Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (for the women of childbearing potential).",{"count":22,"type":23},[26],"The goal of this study is to learn if a mouthwash works to alleviate gingivitis in adults. It will also learn about the safety of the product. The main question it aims to answer is:\n\n• Does the mouthwash help to improve signs of gingivitis?\n\nParticipants will:\n\n* Use mouthwash daily for 4 weeks\n* Visit the clinic on the established days during 4 weeks for check-ups and evaluation",[30],"2026-04-22",{"date":320,"type":42},"2026-04-27",{"date":322,"type":23},"2026-04-03",{"date":324,"type":23},"2026-07",{"name":238,"class":181},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":50},"100635181","is-professional-tooth-cleaning-necessary-for-managing-gingivitis-gingival-inflammation-if-subjects-use-intelligent-toothbrushes-100635181","NCT07549347","Is Professional Tooth Cleaning Necessary for Managing Gingivitis (Gingival Inflammation) if Subjects Use Intelligent Toothbrushes?","Optimal Oral Care Regimen With or Without Professional Mechanical Plaque Removal in Managing Gingivitis (Gingival Inflammation): A Non-inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. ≧18 years old and \\\u003C 65 years old\n2. Gingivitis, Stage I and Localized Stage II Periodontitis\n3. With more than 20 teeth\n4. Agree to use the electronic I-brush with the Oral-B APP\n\nExclusion Criteria:\n\n1. Presence of any systemic disease that can alter the outcome of periodontal treatment\n2. Pregnancy or lactation during the study\n3. Having received antibiotics within the previous 3 months\n4. Having received professional periodontal treatment within the previous 3 months\n5. With ongoing orthodontic treatment","64 Years",{"count":335,"type":23},92,[26],"Periodontitis is highly prevalent and develops from plaque-induced gingivitis. Managing gingivitis is key to preventing periodontitis and its complications. Professional mechanical plaque removal (PMPR) with oral hygiene guidance is effective for gingivitis, but large-scale implementation-especially in China-faces challenges such as workforce shortages. Meanwhile, patient compliance with daily oral hygiene remains poor. An optimal oral care regimen featuring an intelligent electric toothbrush (i-Brush) has shown promise in enhancing self-care adherence and efficiency. However, it remains unclear whether PMPR is still necessary when used in conjunction with this optimal oral care regimen. This study aims to verify whether the i-Brush-based regimen is non-inferior to the combination of PMPR and the regimen in improving gingival inflammation in gingivitis and stage I periodontitis.",[30,29],[340,341,342,343,344],"artificial intelligence","internet of things network","oral hygiene instruction","professional mechanical plaque removal","mobile health","2026-04-17",{"date":298,"type":42},{"date":348,"type":42},"2026-03-09",{"date":215,"type":23},{"name":305,"class":49},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":225,"enrollmentInfo":358,"targetDuration":4,"studyType":24,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":50},"100631355","effect-of-morus-nigra-mouthwash-on-gingivitis-treatment-100631355","NCT07499596","Effect of Morus Nigra Mouthwash on Gingivitis Treatment","Evaluation of the Efficacy of Morus Nigra Mouthwash as an Adjunct to Scaling and Root Planing in the Treatment of Gingivitis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosis of generalized gingivitis (Gingival Index \\> 1).\n* Presence of at least 20 natural teeth.\n* Systemically healthy individuals.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Smoking or use of tobacco products.\n* Presence of periodontitis (no clinical attachment loss).\n* Use of antibiotics or anti-inflammatory drugs in the last 6 months.\n* Pregnancy or lactation.\n* History of allergy to Morus nigra or mouthwash components.\n* Systemic diseases (Diabetes, cardiovascular diseases, etc.).",{"count":22,"type":23},[26],"The aim of this study is to evaluate the clinical, microbiological, and biochemical effects of Morus nigra (black mulberry) mouthwash when used as an adjunct to non-surgical periodontal treatment (scaling and root planing - SRP) in patients with generalized gingivitis. Participants will be randomly assigned to two groups: one receiving SRP only, and the other receiving SRP plus Morus nigra mouthwash twice daily for 14 days. Clinical parameters, cytokine levels in gingival crevicular fluid (TNF-alpha, IL-1beta, IL-10), and subgingival bacterial load will be assessed at baseline, 1 month, and 3 months.",[30],[363,364,365],"Morus nigra","Mouthwash","Cytokines","2026-04-08",{"date":368,"type":42},"2026-04-13",{"date":370,"type":42},"2026-01-15",{"date":372,"type":23},"2026-07-15",{"name":217,"class":49},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":381,"targetDuration":4,"studyType":24,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":392,"locationsCount":50},"100631318","phase-3-efficacy-of-a-toothpaste-in-reducing-plaque-gingivitis-and-gingival-bleeding-100631318","NCT07499115","Efficacy of a Toothpaste in Reducing Plaque, Gingivitis, and Gingival Bleeding","Clinical Investigation of the Efficacy of a Toothpaste Containing Chitosan in Reducing Plaque, Gingivitis, and Gingival Bleeding","Inclusion Criteria:\n\n* Male or female, aged 18-70 years (inclusive).\n* Available for the duration of the study.\n* Able to understand and willing to read and sign the Informed Consent Form after the nature of the study has been fully explained.\n* Willing to comply with all study procedures and clinical examination schedules.\n* Good general health (absence of any condition that, in the opinion of the study examiner, might pose risk during participation; e.g., certain heart conditions, valve\u002Fhip replacements).\n* Presence of at least 20 natural teeth (excluding third molars) with scorable facial and lingual surfaces.\n* Mean Modified Gingival Index (MGI, Lobene) ≥ 2.0 and Mean Modified Plaque Index (MPI, Turesky) ≥ 1.5 at screening.\n* Willing and able to complete study questionnaires on product usage experience during routine toothbrushing.\n\nExclusion Criteria:\n\n* Pregnant or lactating.\n* Use of tobacco products.\n* History of alcohol or drug abuse.\n* Any medical condition (e.g., significant heart or liver disease, bleeding disorders, blood dyscrasias) or current medication use that, in the investigator's judgment, may compromise subject safety or the quality of study results.\n* Medical condition requiring pre-medication prior to dental visits\u002Fprocedures.\n* History of allergy to oral hygiene products.\n* Use of anti-inflammatory, immunosuppressive, antimicrobial, or anticoagulant drugs, or antibiotics within 30 days prior to study start or during the study.\n* Ongoing use of medications known to affect gingival tissues (e.g., calcium channel blockers, phenytoin, cyclosporine).\n* Presence of orthodontic bands or removable partial dentures.\n* Tumors of the soft or hard tissues of the oral cavity.\n* Five or more carious lesions requiring immediate restorative treatment.\n* More than two periodontal pockets (\\>4 mm) with bleeding on probing.\n* Any gingival condition (e.g., hyperplasia or overgrowth) that would interfere with clinical assessment.\n* Participation in another clinical study with an oral care indication or test panel within 30 days prior to study start.\n* Medical condition that prohibits abstaining from eating or drinking for up to 2 hours.",{"count":382,"type":23},90,[138],"To assess the efficacy of a toothpaste containing chitosan in reducing plaque, gingivitis, and gingival bleeding, compared with Colgate Cavity Protection Toothpaste",[386,30],"Plaque, Dental","2026-04-07",{"date":368,"type":42},{"date":390,"type":23},"2026-04",{"date":324,"type":23},{"name":180,"class":181},{"id":394,"slug":395,"hasResults":12,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":133,"minAge":20,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":24,"phases":402,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":50},"100621955","cheer-oral-health-in-pregnancy-study-100621955","NCT07377344","CHEER Oral Health in Pregnancy Study","Closing Health Equity Through Empowering Oral Health for Maternal Wellness","CHEER","Inclusion Criteria:\n\n1. Pregnant individuals aged 18 years or older with indications of periodontal diseases (gingivitis or mild periodontitis, moderate to severe periodontitis)\n2. Less than 20 weeks pregnancy at time of enrollment\n3. Has dental insurance (Medi-Cal or private coverage)\n4. Willing and able to provide informed consent\n5. Planning to receive ongoing prenatal care at study-affiliated clinics\n6. Access to a mobile phone for receiving text messages\n\nExclusion Criteria:\n\n1. Presence of systemic diseases or medical conditions that require antibiotic prophylaxis for dental procedures\n2. Current immunosuppressive therapy\u002Fuse of anti-inflammatory medications\n3. Receipt of active periodontal treatment within the past 6 months\n4. Complete edentulism (no natural teeth)\n5. Unable to read and write English\n6. Less than 9th grade education\n7. Enrollment in another oral interventional study",{"count":269,"type":23},[26],"Many pregnant people don't get the dental care they need, even though it's safe and important. The CHEER Study offers free dental check-ups, cleanings, and supplies to help participants take care of their teeth and gums during pregnancy. The purpose of this research study is to compare two types of noninvasive oral health interventions to evaluate their effectiveness. We want to learn if one method is more effective in supporting oral health and improving pregnancy outcomes. There are two aims of this study:\n\nAim 1: To evaluate whether a structured oral health intervention reduces periodontal inflammation during pregnancy and postpartum in pregnant people with indicators of periodontal disease.\n\nAim 2: To assess whether a structured oral health intervention is associated with changes in oral health behaviors or birth outcomes in pregnant people with periodontal disease.",[30,405,406,407,408,292,409],"Dental Health","Pregnancy","Pregnancy Outcomes","Randomized Controlled Trial","Gum Disease","2026-04-01",{"date":387,"type":42},{"date":413,"type":23},"2026-06-01",{"date":415,"type":23},"2028-06-01",{"name":417,"class":49},"University of California, San Francisco",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":425,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":437},"100553033","application-of-ultra-high-frequency-ultrasonography-uhfus-to-the-study-of-gingival-tissues-100553033","NCT06480825","Application of Ultra-high Frequency Ultrasonography (UHFUS) to the Study of Gingival Tissues","Ulta-High Frequency Ultrasound Assessment of Normal Versus Gingivitis Affected Gingival Tissues","Inclusion Criteria:\n\n* males or females of age \\> 18 years\n* presence of at least 20 teeth\n* full-mouth plaque score (FMPS) \\>50%\n* FMBS \\>30%\n* ability and willingness to give informed consent\n\nExclusion Criteria:\n\n* pregnancy or breastfeeding\n* pharmacological treatment with antinflammatory drugs, statins, or either local or systemic antibiotics (within the previous 30 days)\n* smoking habit\n* dental or periodontal condition requiring immediate treatment\n* refusal to be enrolled in the study",{"count":426,"type":23},40,"Gingival inflammation triggered by the accumulation of bacterial is the primary risk factor for the development of periodontitis. Clinically, localized signs of inflammation limited to the gingiva, presence of significant bacterial plaque load, and stable attachment levels on the periodontium can be observed in course of gingivitis. The aim of the present study is to compare clinical aspects of gingival tissue in healthy patients versus patients with gingivitis to assess the ultrastructural variations present in course of inflammation.\n\nPatients with gingivitis and healthy controls will be enrolled. All patients will undergo ultra-high frequency ultrasonographic scans (70 MHz) of gingival tissue on three areas per dental arch (anterior, middle right, middle left). Gingival thickness, echogenicity, and vascularization assessed through resisitive index will be evaluated.",[30,29],"2026-03-31",{"date":410,"type":42},{"date":432,"type":42},"2024-04-02",{"date":434,"type":23},"2028-07",{"name":436,"class":49},"University of Pisa",2,{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":445,"targetDuration":4,"studyType":24,"phases":446,"briefSummary":447,"conditions":448,"keywords":450,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":457,"leadSponsor":458,"locationsCount":50},"100632065","evaluation-of-the-safety-and-efficacy-of-sali-10-probiotic-lozenges-100632065","NCT07508839","Evaluation of the Safety and Efficacy of SALI-10 Probiotic Lozenges","Evaluation of the Safety and Efficacy of SALI-10 Probiotic Lozenges: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Male or female volunteers aged 18-70 years\n2. In good general health, ASA I\n3. Non-smokers\n4. Fluent in English\n5. For sexually active volunteers of childbearing potential, one of the following methods must be used to prevent pregnancy during the study by participants.\n\n   1. Post-menopausal\n   2. hormonal birth control (oral, injectable, transdermal, intra-vaginal) or intrauterine device must be in use at least 30 days prior to first study drug administration;\n   3. barrier methods must be in use at least 14 days prior to study drug administration;\n   4. that vasectomy on the male partner must be completed 3 months prior to first study drug administration;\n   5. or in the alternative that a 0 sperm count for the male partner will suffice\n\nExclusion Criteria:\n\n1. Presence of orthodontic bands.\n2. Presence of partial removal dentures.\n3. Dental pain at time of screening.\n4. History of allergy to a consumer or personal care products or dentifrice ingredients as determined by the dental profession monitoring the study, or to any of the following: sorbitol, isomalt, dibasic calcium phosphate, potato or potato starch, mint or mint flavour, glyceryl dibehenate, steviol glycosides.\n5. Participation in any other clinical study or test panel within one month before entering the study.\n6. Current use of anti-inflammatory, antibiotics, or antimicrobial drugs or within the last 30 days of enrolment.\n7. Those taking anticoagulant medications and have blood and bleeding disorders\n8. Those who have recently experienced (past 30 days) or will be experiencing (next 90 days) dental, oral, or any type of surgery\n9. History of systemic inflammatory or immune conditions or immunocompromised conditions\n10. Pregnant or nursing women or those planning on getting pregnant.\n11. Use of tobacco products.\n12. Long-term antibiotic or anti-inflammatory therapy.\n13. Medical condition or any current usage of medication that the investigator considers may compromise the subject's safety as well as the quality of the study results (note, only Advil and Tylenol are allowed during the study for analgesia)\n14. Medication or Natural Health Products (NHPs) that could affect the gingiva like calcium channel blockers, anti-epileptic therapy etc.\n15. Participants who are experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain.\n16. Presence of active infections\n17. Use of any probiotic\n18. Use of anti-plaque\u002Fanti-gingivitis products\n19. Subjects who must receive dental treatment during the study elates\n20. Concurrent orthodontic treatment\n21. Untreated carious lesions and\u002For inadequate restorations on maxillary posterior teeth\n22. Periodontal disease (periodontal pockets, probing depth (PD) \\\u003C 3.0 mm on at least one tooth\u002Fsite, presence of Clinical Attachment Loss (CAL) = 0 mm, or periodontal disease history)",{"count":227,"type":23},[26],"Gingivitis is among the most common oral conditions, affecting 50-90% of adults globally. It is a reversible inflammatory disease triggered primarily by the accumulation of microbial plaque on teeth and gingival tissues. Standard treatment involves plaque reduction and maintenance of oral hygiene, often supplemented with antimicrobial therapeutics to prevent disease progression. While plaque control remains the cornerstone of prevention, emerging research points to certain beneficial microbes that may protect gingival health. Notably, Streptococcus species have been associated with both antimicrobial and anti-inflammatory activities, suggesting their potential as oral probiotics.\n\nRecent investigations have focused on a novel strain, Streptococcus salivarius SALI-10, which produces a lantibiotic called Salivaricin 10. This peptide exhibits unique immunomodulatory properties. In murine models, Salivaricin 10 was shown to enhance neutrophil recruitment and activity while directing monocytes toward the M2 pro-resolution macrophage phenotype, a cell population integral to tissue repair and late-stage wound healing. Such effects highlight the potential of SALI-10 to reduce gingival inflammation while fostering microbial balance.\n\nThe concept of employing S. salivarius strains in oral health is not entirely new. Other variants isolated from the oral cavities of healthy individuals produce lantibiotics with lanthionine or β-methyllanthionine residues that demonstrate antimicrobial effects against pathogens. Clinical investigations have explored these probiotic strains for halitosis, plaque control, and gingivitis, reporting safety and efficacy. Moreover, salivaricin-producing strains are considered valuable in the ongoing search for alternatives to conventional antibiotics in light of increasing resistance.\n\nUnderstanding the microbial ecology of gingivitis helps contextualize this therapeutic potential. In health, gram-positive bacteria, particularly Streptococcus species, dominate the oral microbiome. Gingivitis involves a shift toward gram-negative periopathogens such as Porphyromonas, Tannerella, Treponema, and Prevotella. This dysbiosis provokes an inflammatory cascade characterized by neutrophil infiltration, tissue damage, and, if unresolved, progression to periodontitis. A recent human experimental gingivitis study revealed distinct host response phenotypes. Participants retaining beneficial Streptococcus species, such as S. sanguinis and S. oralis, experienced reduced periopathogen emergence and milder inflammation. By contrast, participants who lost these protective bacteria demonstrated greater inflammatory severity, underscoring the critical role of Streptococcus persistence in oral homeostasis.\n\nNeutrophils, the most abundant immune cells in periodontal tissues, are central to this dynamic. Their numbers increase proportionally with gingivitis severity. Importantly, Health Canada has recently recognized salivary neutrophil activity as a valid biomarker for assessing inflammatory burden and risk of gingivitis or periodontal disease. This regulatory approval highlights the growing emphasis on immune function as both a diagnostic measure and therapeutic target in oral health.\n\nAgainst this backdrop, S. salivarius SALI-10 presents a compelling intervention strategy. Its hypothesized benefits include reducing inflammation via promotion of the M2 macrophage phenotype, suppressing periopathogen growth through competitive exclusion and Salivaricin 10 production, and mitigating halitosis by blocking volatile sulfur compound-producing bacteria. To evaluate these benefits, a proposed study design involves administering a twice-daily lozenge , one in the morning and one in the evening, after brushing a tongue scraping each containing 3 billion CFU of SALI-10 over a four-week period.\n\nIn summary, gingivitis remains highly prevalent but reversible. Beyond traditional hygiene approaches, microbial therapeutics such as S. salivarius SALI-10 may offer a dual antimicrobial and anti-inflammatory benefit. By promoting immune resolution and reshaping the microbial community, SALI-10 could emerge as a novel probiotic strategy in maintaining oral health and addressing the limitations of conventional antimicrobial therapies.",[30,449],"Halitosis",[451,452],"Oral Health","Probiotics","2026-03-27",{"date":455,"type":42},"2026-04-02",{"date":390,"type":23},{"date":96,"type":23},{"name":459,"class":181},"Ostia Sciences",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":466,"enrollmentInfo":467,"targetDuration":4,"studyType":24,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":50},"100631497","comparison-of-the-effects-of-oral-hygiene-regimens-on-clinical-immunomodulatory-and-microbial-outcomes-and-oral-tolerance-in-people-with-gingivitis-100631497","NCT07501455","Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis","Inclusion Criteria:\n\n2\\. Adequate oral hygiene (i.e., brush teeth daily and exhibit no signs of gross oral neglect).\n\n3\\. Mean Modified Gingival Index (MGI) is greater than or equal to 2.00 at screening visit and reconfirmed at baseline visit.\n\n4\\. Bleeding upon probing (BOP) is greater than or equal to 30% at the screening visit.\n\n5\\. Diagnosis of gingivitis (confirmed by MGI and BOP) at the screening visit and reconfirmed at the baseline visit.\n\n6\\. Able to read and understand English. 7. Subject has signed the written informed consent (ICD) and indicated their agreement with the terms of the study and the study procedures listed and photograph release including the Health Insurance Portability and Accountability Act (HIPAA) disclosure prior to any study-related procedures.\n\n8\\. Generally, in good overall health based on the medical history reported by the subject.\n\n9\\. Has at least 18 natural teeth (not counting 3rd molars) with scorable facial and lingual surfaces.\n\n10\\. Willingness to use the assigned products according to instructions, availability for appointments, agreement to follow the subject responsibilities and likelihood of completing the clinical trial\n\nExclusion Criteria:\n\n1. Significant oral soft tissue pathology or active dental caries, based on the dentist's visual examination and at the discretion of the Investigator.\n2. History of significant adverse reactions, including sensitivity or suspected allergies, following use of oral hygiene products such as toothpastes, mouth rinses, and red food dye.\n3. Periodontitis, as determined by more than 2 sites with a probing depth greater than 4mm.\n4. Regular consumption of probiotics supplements within one week prior to screening. Subjects can be rescreened if they fulfill this criterion.\n5. Dental prophylaxis within 4 weeks prior to screening. Subjects can be rescreened if they fulfill this criterion.\n6. Subjects who wear orthodontic bands, fixed retainers, removable orthodontic appliances, clear aligners or night guards or subjects who have had significant (based on the examiner or PI's oral exam) cosmetic restorations.\n7. History of medical conditions requiring prophylactic antibiotic coverage prior to dental procedures.\n8. Self-reported tobacco, cannabis, smokeless tobacco use, including snuff, chewing tobacco, vaping, and e-cigarette usage.\n9. Suspected alcohol or substance abuse.\n10. Significant unstable or uncontrolled medical condition which may interfere with a subject's participation in the study, at the discretion of the Investigator, including a history of or a concurrent health\u002Fother condition\u002Fsituation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study.\n11. Has self-reported Type 1 or Type 2 diabetes or is on an anti-diabetic medication (i.e., metformin, insulin, Glucophage, etc.)\n12. Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including:\n\n    * Non-steroidal anti-inflammatory drugs within 5 days before Visit 1 (81mg of aspirin is allowed).\\*\n    * Use of Immunosuppressive, or steroidal drugs therapy during the study or within 2 months before Visit 2. \\* Intermittent use (\\\u003C3 times per week) of certain anti-inflammatory medications is acceptable at the discretion of the investigator. Use of anticoagulant therapy within 1 month of screening visit or during the study.\n    * Use of systemic antibiotics within 1 month of screening visit and during the entire study.\n13. Is self-reported to be pregnant, in lactation, planning to become pregnant during the study, or positive pregnancy urine tests (females of child-bearing potential only):\n\n    * For females: Postmenopausal state (i.e., at least 1 year without menses without an alternative medical condition prior to the first study IP administration) or premenopausal\u002Fperimenopausal state with an effective means of contraception.\n    * Females of childbearing potential must be using a medically acceptable method of birth control for at least one month prior to Visit 1 and agree to continue using this method during their participation in the clinical trial. Medically acceptable forms of birth control that may be used by the subject and\u002For his\u002Fher partner include:\n\n      * Double barrier method (condoms, diaphragm or cervical cap with spermicide)\n      * Hormonal prescription contraceptives (i.e., oral, injectable, implanted, patch or vaginal ring hormone therapy)\n      * Intrauterine device (IUD)\n      * Surgical sterilization (e.g., vasectomy that has been confirmed effective by sperm count check, tubal ligation, hysterectomy and\u002For bilateral oophorectomy)\n      * Abstinence\n    * For males: No pregnant or lactating spouse or partner at screening and willingness to utilize an acceptable form of birth control with spouse or any potential partner during the study and for 30 days thereafter.\n14. Participation in any clinical trial within 30 days of the Screening visit.\n15. Subjects who were previously randomized into one of the study products as part of this study.\n16. Subjects who are related to the people who are involved directly or indirectly with the conduct of this study (i.e., principal Investigator, sub-investigators, study coordinators, other site personnel, employees of Kenvue, contractors of Kenvue, and the families of each).\n17. Subjects within the same household as other subjects enrolled in the study at the same time.","60 Years",{"count":468,"type":23},250,[26],"This study is a six-week, double-blind, randomized, parallel-group controlled clinical study. The objective of this study is to evaluate the changes to the oral microbiome, inflammatory mediators, gingival health indices and to assess oral tolerance after 4 weeks of twice daily use of differing oral hygiene regimens including mouthwash compared to a control group. A follow-up assessment will be completed 2 weeks after cessation of treatments.",[472,365,172,30,473],"Microbiome","Gingival Bleeding",{"date":475,"type":42},"2026-03-30",{"date":477,"type":42},"2026-02-26",{"date":255,"type":23},{"name":480,"class":181},"Kenvue Brands LLC",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":24,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":502,"leadSponsor":504,"locationsCount":50},"100628986","effect-of-individually-trained-oral-prophylaxis-itop-on-gingival-health-in-orthodontic-patients-100628986","NCT07468773","Effect of Individually Trained Oral Prophylaxis (iTOP) on Gingival Health in Orthodontic Patients","Effect of Individually Trained Oral Prophylaxis (iTOP) Versus Conventional Oral Hygiene Instruction on Gingival Health in Orthodontic Patients Using Calibrated Interdental Brushes: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Adults aged 18 years or older\n2. Patients undergoing fixed orthodontic treatment\n3. Diagnosis of biofilm-induced gingivitis\n4. Presence of interdental spaces suitable for calibrated interdental brush use\n5. Ability and willingness to perform oral hygiene procedures and attend follow-up visits\n6. Provision of written informed consent\n\nExclusion Criteria:\n\n1. Presence of systemic diseases affecting gingival health (e.g., uncontrolled diabetes)\n2. Use of medications known to influence gingival conditions (e.g., phenytoin, cyclosporine, calcium channel blockers)\n3. History of chemotherapy or radiotherapy in the head and neck region\n4. Current smokers\n5. Pregnant or lactating women\n6. Patients with physical or cognitive disabilities affecting oral hygiene performance\n7. Use of additional professional oral hygiene interventions or antimicrobial mouth rinses during the study period",{"count":227,"type":23},[26],"This randomized controlled clinical trial aims to evaluate the effectiveness of individualized oral hygiene education using the Individually Trained Oral Prophylaxis (iTOP) method compared with conventional oral hygiene instruction using model demonstration and video-based education in orthodontic patients diagnosed with gingivitis.\n\nSixty orthodontic patients underwent professional mechanical plaque removal and received oral hygiene instruction using calibrated interdental brushes. Participants were randomly assigned to either the iTOP training group or the conventional education group.\n\nClinical outcomes including Approximal Plaque Index (API), Gingival Index (GI), and Full Mouth Bleeding Score (FMBS) were assessed at baseline and after three months to determine the effectiveness of the educational interventions on plaque control and gingival health.",[30,492],"Orthodontic Treatment",[494,495,496,497,498],"Interdental Brushes","iTOP","Oral Hygiene Education","Approximal Plaque Index","Plaque Control",{"date":500,"type":42},"2026-03-13",{"date":475,"type":23},{"date":503,"type":23},"2026-09-30",{"name":505,"class":49},"Gulf Medical University",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":19,"minAge":20,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":24,"phases":516,"briefSummary":517,"conditions":518,"keywords":520,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":50},"100501744","novosyn-quick-versus-monosyn-quick-suture-material-in-resective-periodontal-surgery-100501744","NCT05813236","NOVOSYN® Quick Versus MONOSYN® Quick Suture Material in Resective Periodontal Surgery","Randomized, Monocentric, Double Blinded, Prospective Study to Evaluate the Early Wound Healing After the Utilization of NOVOSYN® Quick Versus MONOSYN® Quick Suture Material in Resective Periodontal Surgery","NOQMOQS","Inclusion Criteria:\n\n* Adult patient undergoing resective periodontal surgery abd one of the incisions below has been performed:\n* Crestal incision\n* Vertical incision\n* Intrasulcular incision\n* Submarginal incision\n* Written informed consent regarding the data collection for the RCT\n\nExclusion Criteria:\n\n* Emergency surgery.\n* Pregnancy.\n* Breastfeeding\n* Patients taking medication that might affect wound healing.\n* Patients having a condition that might affect wound healing.\n* Patients with hypersensitivity or allergy to the suture material",{"count":515,"type":23},84,[26],"The aim of this study is to prove that Novosyn Quick and Monosyn Quick are equivalent in early wound healing in adult patients undergoing resective periodontal surgery.\n\nIn order to show equivalence between Novosyn Quick and Monosyn Quick EHS, which is composed of 3 parameters: clinical signs of reepithelization, clinical signs of haemostasis and clinical signs of inflammation, will be calculated for each suture 10 ± 5 days postoperatively and cannot differ more than 2 points.\n\nFurthermore, complications, the handling of the suture material, pain, satisfaction of the patient and bacterial contamination of the thread (optional) will also be assessed as secondary objectives.",[30,519,112],"Gingival Diseases",[521],"Resective periodontal surgery","2026-03-05",{"date":524,"type":42},"2026-03-06",{"date":526,"type":42},"2023-06-28",{"date":528,"type":23},"2026-12",{"name":530,"class":181},"Aesculap AG",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":106,"enrollmentInfo":538,"targetDuration":4,"studyType":24,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":547,"locationsCount":4},"100628194","phase-3-a-study-to-investigate-stannous-fluoride-containing-toothpaste-on-antibacterial-effects-in-the-different-regions-of-the-mouth-100628194","NCT07458464","A Study to Investigate Stannous Fluoride Containing Toothpaste on Antibacterial Effects in the Different Regions of the Mouth","A Clinical Study to Investigate Stannous Fluoride Containing Toothpaste on Antibacterial Effects in the Different Regions of the Mouth as Compared to Colgate Cavity Protection Toothpaste.","Inclusion Criteria:\n\n* Male and female subjects, ages 18-70, inclusive.\n* Subject is available during study duration and has no allergies to oral hygiene formulations.\n* A minimum of 20 natural teeth with facial and lingual scorable surfaces.\n* A willingness to read, understand, and sign the Informed Consent Form after the nature of the study has been fully explained to them. Subject should demonstrate a willingness to comply with all study procedures and clinical examination schedules.\n* Subjects with a baseline whole mouth scores of dental plaque of 1.5 or more \\[Turesky Modification of Quigley-Hein\\] and gingivitis index of 1.0 or more \\[Loe-Silness\\].\n\nExclusion Criteria:\n\n* Participation in any other clinical study or test panel including clinical studies with oral hygiene formulations within the one month prior to entry into the study.\n* History of dental prophylaxis or treatments in the past month or during study duration.\n* History of medical treatments including antibiotic, anti-inflammatory or anticoagulant therapy during the month preceding study enrollment.\n* Subjects scheduled for medical procedures for the duration of the study.\n* Difficulty complying with study procedures and examinations such as excessive gagging during oral assessment etc.\n* History of significant adverse effects following use of oral hygiene products such as toothpastes and mouth rinses. Allergy to personal care\u002Fconsumer products or their ingredients.\n* History of diabetes or hepatic or renal disease, or medical or inflammatory conditions or transmittable diseases, e.g. heart disease or AIDS.\n* History of rheumatic fever, heart murmur, mitral valve prolapse or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures.\n* Oral soft tissue pathology.\n* History of active or severe periodontal disease and loose teeth.\n* Gross dental caries, severe generalized cervical abrasion and\u002For enamel abrasion, large fractured or temporary restorations (based on visual examinations).\n* Fixed or removable orthodontic appliance or removable partial dentures.\n* Self-reported pregnancy or lactation.\n* Subjects known to be an alcoholic, or a recovering alcoholic.",{"count":167,"type":23},[138],"The clinical study will examine the effects of brushing with randomly assigned test toothpaste on the bacteria on the dental plaque, tongue, cheek, gum surface, and in saliva",[172,30],"2026-03-04",{"date":348,"type":42},{"date":545,"type":23},"2026-05",{"date":94,"type":23},{"name":180,"class":181},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":466,"enrollmentInfo":555,"targetDuration":4,"studyType":24,"phases":556,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":4},"100628401","early-phase-1-stingless-bee-honey-mouth-rinse-on-gingivitis-100628401","NCT07461155","Stingless Bee Honey Mouth Rinse on Gingivitis","The Development of Anti-Inflammatory and Natural-based Mouth Rinse From Stingless Bee Honey","Inclusion Criteria:\n\n* 18 to 60 years old patients\n* BPE code 2 and\u002For below\n* Presence of at least 20 natural teeth\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Smoking\n* Mucosal lesion\n* Allergic to honey\n* Physical or mental disabilities",{"count":227,"type":23},[557],"EARLY_PHASE1","The currently used chemical mouth rinse, chlorhexidine, was prescribed widely among dental practitioners for its ability to kill bacteria. However, chlorhexidine prolonged use is limited due to its adverse events such as extrinsic tooth staining, taste disturbance, effects on the oral mucosa such as soreness, irritation, mild desquamation, mucosal ulceration, general burning sensation and calculus formation. Thus, an alternative natural active agent is needed to produce mouth rinse with less side effect but offer similar disease prevention effect. This comprehensive four-phase research initiative aims to advance the development and evaluation of a stingless bee honey mouth rinse, particularly focusing on improved formulation and tested in vitro and clinically. In Phase I and II, the mouth rinse development involve the improved formulation by xylitol addition in the formulation with physicochemical assessment such as shelf-life followed by antimicrobial activities against Staphylococcus aureus and cytotoxicity evaluation against oral keratinocytes. Phase III focuses on clinical trial in a pilot study that will be performed on twenty volunteers divided to two groups; control and test group who will be using mouth rinse as adjunctive periodontal therapy agent (TRL 5). Comparative analyses will assess the adjunctive effect of this stingless bee honey mouth rinse in periodontal therapy. A commercially packaged mouth rinse will be designed and produced in collaboration with Bayu Gagah Marketing and will be given to the public as free samples to obtain feedback and validate its further use in the health industry.",[30],{"date":561,"type":42},"2026-03-10",{"date":563,"type":23},"2026-07-06",{"date":565,"type":23},"2027-11-30",{"name":567,"class":49},"Ministry of Higher Education, Malaysia",{"id":569,"slug":570,"hasResults":12,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":133,"minAge":20,"maxAge":576,"enrollmentInfo":577,"targetDuration":4,"studyType":24,"phases":578,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":596,"locationsCount":50},"100598257","lactoferrin-based-oral-care-for-periodontal-health-in-pregnancy-100598257","NCT07069140","Lactoferrin-Based Oral Care for Periodontal Health in Pregnancy","Effectiveness of an Oral Care Protocol Based on Lactoferrin Toothpaste and Mouthwash in Pregnant Women for the Prevention of Periodontal Disease: A Randomized Controlled Clinical Trial","LBC-PREG","Inclusion Criteria:\n\n* Pregnant women aged between 18 and 45 years\n* Gestational age between 14 and 28 weeks at the time of enrollment (second trimester)\n* Diagnosis of periodontitis according to the 2017 World Workshop classification (Stages I-III, Grades A-B)\n* Presence of at least 20 natural teeth\n* Willingness to comply with study procedures and attend follow-up visits\n* Signed informed consent\n\nExclusion Criteria:\n\n* History of systemic diseases that could affect periodontal status (e.g., diabetes mellitus, immunosuppression)\n* Antibiotic or anti-inflammatory therapy within 3 months prior to enrollment Current use of probiotics, antioxidant supplements, or medicated mouthwashes\n* Periodontal treatment within 6 months before enrollment\n* High-risk pregnancy or pregnancy complications (e.g., preeclampsia, gestational diabetes)\n* Smoking or tobacco use\n* Known allergy to any of the investigational product components\n* Participation in another clinical trial within the previous 3 months","45 Years",{"count":426,"type":23},[26],"This randomized controlled clinical trial aims to evaluate the effectiveness of a lactoferrin-based oral hygiene protocol in improving periodontal health during pregnancy. Forty pregnant women between the fourth and eighth month of gestation will be enrolled and randomly assigned to one of two groups. The trial group will undergo professional dental cleaning every three months and will perform home oral hygiene using both a lactoferrin-based toothpaste and a lactoferrin-based mouthwash (Emoform Glic) twice daily. The control group will follow the same schedule of professional dental cleanings but will use only the lactoferrin-based toothpaste (Emoform Glic) at home. The primary objective is to assess the reduction in dental plaque, measured by the Plaque Index (PI). Secondary outcomes include improvements in gingival inflammation, probing pocket depth, clinical attachment level, and other periodontal indices. Participants will be followed for six months, with evaluations conducted at baseline, 1, 3, and 6 months.",[406,292,30,581],"Oral Microbiota",[583,406,292,581,584,30,585,586,364,587,588,408,589],"Lactoferrin","Dental Plaque","Non-surgical Periodontal Therapy","Toothpaste","LBC Complex","Maternal Oral Health","Oral Hygiene in Pregnancy","2026-02-19",{"date":592,"type":42},"2026-02-20",{"date":594,"type":42},"2025-07-30",{"date":68,"type":23},{"name":597,"class":49},"University of Pavia",{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":133,"minAge":20,"maxAge":4,"enrollmentInfo":606,"targetDuration":4,"studyType":24,"phases":607,"briefSummary":608,"conditions":609,"keywords":612,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":621,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":625,"locationsCount":50},"100595200","effectiveness-of-coenzyme-q10-and-probiotics-in-periodontal-therapy-during-pregnancy-100595200","NCT07029360","Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy","Adjunctive Use of Coenzyme Q10 and Probiotics to Improve Periodontal Health in Pregnant Women: A Randomized Controlled Trial","PREG-Q10","Inclusion Criteria:\n\n* Pregnant women between the 4th and 8th month of gestation\n* Age ≥ 18 years\n* Able to understand and communicate in Italian and\u002For English\n* Willing to provide written informed consent\n* Good compliance and willingness to follow study instructions\n\nExclusion Criteria:\n\n* Presence of cardiac pacemakers\n* Diagnosed psychological, neurological, or psychiatric disorders\n* Ongoing oncological therapy\n* Use of bisphosphonates within the last 12 months\n* Poor motivation or low compliance\n* Substance abuse (drugs or alcohol) or lifestyle incompatible with study requirements",{"count":426,"type":23},[26],"This randomized controlled clinical trial aims to evaluate the effectiveness of adjunctive coenzyme Q10 and probiotic supplementation (Limosilactobacillus reuteri Prodentis®) in improving periodontal health in pregnant women undergoing non-surgical periodontal therapy. Forty participants will be randomly assigned to two groups: the test group will receive professional oral hygiene every three months along with a coenzyme Q10-based toothpaste and daily probiotic supplementation; the control group will follow the same protocol without probiotics. The primary outcome is the reduction of the Plaque Index (PI), while secondary outcomes include Bleeding on Probing (BoP), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), gingival inflammation (MGI, PMGI), plaque distribution (PCR%, API), and gingival recession (R). The study duration is 6 months. The goal is to assess whether this combined therapy can promote a balanced oral microbiota and enhance periodontal health during pregnancy.",[406,292,30,584,452,610,611],"Coenzyme Q10","Microbiota",[613,614,610,584,615,30,616,611,617,581,618,498,619,406,620,452,408],"Bleeding on Probing","Clinical Attachment Loss","Gingival Inflammation","Limosilactobacillus reuteri","Non-Surgical Periodontal Treatment","Periodontal Therapy","Plaque Index","Pregnant Women",{"date":592,"type":42},{"date":623,"type":42},"2025-07-01",{"date":68,"type":23},{"name":597,"class":49}]